News Sentiment

APGE sentiment intelligence

Apogee Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 72 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 134.00 Week of 17 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 64

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend active

+0.3% over one week, +48.3% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Apogee Therapeutics stock hits all-time high at 134.34 USD

Market Reaction

Balanced read

54/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction 0.3% Price digesting
Trend fit Trend active 48.3% over four weeks
Fair value 168.6% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 50
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 64
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
Market source 10
TradingView 8
Investing.com 4
Motley Fool 3
timothysykes.com 3
Investing.com Nigeria 2
StocksToTrade 2

Event Lens

What the news is about

Classified themes
Market update 43
Earnings 18
Deals and strategy 8
Capital return 1
Macro sensitivity 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 72
Investing.com Direct company coverage

Apogee Therapeutics stock hits all-time high at 134.34 USD

Apogee Therapeutics stock reached an all-time high of $134.34 USD, marking a significant milestone with a 243% increase over the past year and a market capitalization of $10.05 billion. The company is set to be acquired by AbbVie for $135.11 per share, following advancements in i

Tone
Positive 70/100
Event
Market update
Published
21 Jul 2026 20:11
Source
Investing.com
Quartr Direct company coverage

Apogee Therapeutics (APGE) Proxy filing Summary

This article summarizes the proxy filing for Apogee Therapeutics (APGE), detailing the upcoming annual meeting on June 9, 2026. Key agenda items include the election of three Class III directors, ratification of Ernst & Young LLP as the independent auditor, and an advisory vote o

Tone
Positive 65/100
Event
Market update
Published
18 Jul 2026 03:10
Source
Quartr
Investing.com South Africa Direct company coverage

Form 4 Apogee Therapeutics Inc For: 16 July By Investing.com

This article reports on a Form 4 filing for Apogee Therapeutics Inc. for July 16, as published by Investing.com. It is a brief announcement without further details regarding the contents of the filing. The article indicates the stock symbol APGE.

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 06:11
Source
Investing.com South Africa
Stock Titan Direct company coverage

Apogee Therapeutics (APGE) CMO donates 8,000 shares to donor advised fund

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, reported a gift of 8,000 shares of common stock on July 14, 2026. The shares were transferred to a donor advised fund as a non-market disposition at $0.00 per share. Following this transaction, Dambkowski directly holds

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 00:09
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Apogee Therapeutics stock hits all-time high at 133.88 USD By Investing.com

Apogee Therapeutics stock reached an all-time high of $133.88, with a market capitalization of $10.02 billion, reflecting a 250% return over the past year. This surge is despite InvestingPro data suggesting the stock might be overvalued and in overbought territory, according to i

Tone
Positive 64/100
Event
Market update
Published
15 Jul 2026 05:40
Source
Investing.com Nigeria
Investing.com Direct company coverage

Apogee Therapeutics stock hits all-time high at 133.88 USD

Apogee Therapeutics (APGE) stock reached an all-time high of $133.88, reflecting a 250% return over the past year and a market capitalization of $10.02 billion. Despite its strong performance, InvestingPro suggests the stock might be overvalued, with the RSI indicating it's in ov

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 20:10
Source
Investing.com
Stock Traders Daily Direct company coverage

Understanding Momentum Shifts in (APGE)

This article analyzes momentum shifts for Apogee Therapeutics Inc. (NASDAQ: APGE), noting a near-term neutral sentiment amidst stronger mid and long-term outlooks. It identifies no resistance levels above the current price, suggesting upside potential. The report provides detaile

Tone
Positive 74/100
Event
Market update
Published
12 Jul 2026 05:38
Source
Stock Traders Daily
GuruFocus Direct company coverage

CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE)

Michael Henderson, CEO of Apogee Therapeutics Inc (APGE), sold 20,000 shares of the company on July 8, 2026. This transaction follows a pattern where Henderson has sold a total of 280,000 shares over the past year with no corresponding purchases. The article highlights that there

Tone
Negative 29/100
Event
Market update
Published
11 Jul 2026 02:09
Source
GuruFocus
Market source Direct company coverage

Apogee Therapeutics (APGE) Jumps Into Focus, Is The Stock Fully Valued?

Apogee Therapeutics (APGE) has attracted attention due to significant share price increases recently, prompting investors to re-evaluate its risk and return profile. Currently trading at $133.57, the stock has seen substantial year-to-date and one-year returns. Its price-to-book

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 00:14
Source
Market source
Investing.com Direct company coverage

Apogee Therapeutics CEO Michael Henderson sells $2.67m in stock

Apogee Therapeutics CEO Michael Henderson sold 20,000 shares of company stock worth $2.67 million and gifted 75,046 shares to a donor-advised fund. These transactions occurred as Apogee Therapeutics stock trades near its 52-week high, having gained 250% in the last year, and foll

Tone
Negative 39/100
Event
Market update
Published
11 Jul 2026 00:09
Source
Investing.com
Investing.com Nigeria Direct company coverage

Form 4 Apogee Therapeutics Inc For: 10 July By Investing.com

This article reports on the filing of Form 4 for Apogee Therapeutics Inc. on July 10. The filing, associated with the stock symbol APGE, was published on Investing.com and includes financial market data such as indices, commodities, and currency exchange rates.

Tone
Neutral 50/100
Event
Macro sensitivity
Published
11 Jul 2026 00:09
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Apogee Therapeutics (APGE) CEO logs stock sale and 75,046-share charitable gift

Apogee Therapeutics CEO Michael Thomas Henderson reported a sale of 20,000 shares of common stock at a weighted average price of $133.63, executed under a pre-arranged Rule 10b5-1 trading plan. Additionally, he made a charitable gift of 75,046 shares to a donor-advised fund. Foll

Tone
Negative 39/100
Event
Market update
Published
11 Jul 2026 00:09
Source
Stock Titan
MSN Direct company coverage

AbbVie to buy Apogee Therapeutics for $10.9 billion in cash

AbbVie announced its intent to acquire Apogee Therapeutics for $10.9 billion in cash. This acquisition is significant for AbbVie's portfolio, enhancing its presence in the therapeutics market through Apogee's pipeline. The deal highlights continued consolidation and strategic inv

Tone
Positive 91/100
Event
Deals and strategy
Published
10 Jul 2026 11:40
Source
MSN
Stock Titan Direct company coverage

Wellington-affiliates report 564,326 APGE shares (APGE) ownership update

Wellington Management-affiliated entities have filed a Schedule 13G/A, reporting beneficial ownership of 564,326 shares (0.91%) of Apogee Therapeutics, Inc. (APGE) common stock as of June 30, 2026. The filing indicates shared voting power of 452,388 shares and shared dispositive

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 16:40
Source
Stock Titan
Stock Titan Direct company coverage

T. Rowe Price boosts Apogee Therapeutics holding to 772,969 shares (NASDAQ: APGE)

T. Rowe Price Investment Management, Inc. has reported a beneficial ownership of 772,969 shares of Apogee Therapeutics common stock, representing 1.3% of the class as of June 30, 2026. This information was disclosed in an Amendment No. 2 to a Schedule 13G/A filing, signed on July

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 15:40
Source
Stock Titan
Stock Titan Direct company coverage

FMR LLC reports 2.49M Apogee Therapeutics shares (NASDAQ: APGE)

FMR LLC has filed a Schedule 13G/A, reporting beneficial ownership of 2,493,136.73 shares of Apogee Therapeutics (NASDAQ: APGE) common stock, which represents 4.0% of the class. The filing indicates FMR LLC has sole dispositive power over all these shares and sole voting power ov

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 14:09
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to EBIT forward of Apogee Therapeutics, Inc. – NASDAQ:APGE

This article provides the enterprise value to EBIT forward for Apogee Therapeutics, Inc. (NASDAQ: APGE) based on data from TradingView. It indicates that the data for the given period shows a specific value, change, and percentage change. The article appears to be a financial sna

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 04:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Apogee Therapeutics, Inc. – NASDAQ:APGE

This page from TradingView provides financial information for Apogee Therapeutics, Inc. under the NASDAQ:APGE ticker. It specifically highlights the "Price to earnings forward" metric and indicates that the market is currently closed with no trades. The content is primarily a pla

Tone
Neutral 50/100
Event
Earnings
Published
06 Jul 2026 03:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Apogee Therapeutics, Inc. – NASDAQ:APGE

This article shows the enterprise value to EBITDA forward for Apogee Therapeutics, Inc. (NASDAQ: APGE). It appears to be a financial data point provided by TradingView, indicating a specific valuation metric for the company. The content itself is very minimal, primarily serving a

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 11:39
Source
TradingView
Moomoo Direct company coverage

Apogee Therapeutics | SCHEDULE 13G/A: Others

This article provides an SEC filing snippet for Apogee Therapeutics, specifically referencing a SCHEDULE 13G/A document. The content of the document itself is not provided, only its existence is noted.

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 10:40
Source
Moomoo
TradingView Direct company coverage

Enterprise value to revenue forward of Apogee Therapeutics, Inc. – NASDAQ:APGE

This article focuses on the enterprise value to revenue forward for Apogee Therapeutics, Inc. (NASDAQ: APGE). It appears to be a financial data snippet or a headline from a financial platform like TradingView, providing a direct metric for the company.

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 06:11
Source
TradingView
Finviz Direct company coverage

APGE - Apogee Therapeutics Inc Revenue Breakdown

This article provides a detailed financial breakdown for Apogee Therapeutics Inc (APGE), including its stock performance, market capitalization, key financial ratios, and institutional ownership. It highlights that the company currently has no sales and is operating at a net loss

Tone
Positive 60/100
Event
Earnings
Published
03 Jul 2026 22:10
Source
Finviz